News

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...
Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...
Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...
This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...
The pharmaceutical giant's journey with Celonis has evolved from operational efficiency to enabling enterprise AI ...
The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...
MSD, known as Merck & Co Inc in the United States and Canada, has been in Singapore for 30 years, employs over 1,800 people, ...
Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...
Merck & Co., Inc. recently reported robust earnings, yet the market response was lukewarm. Investors overlooked several positive aspects beneath the surface. Unusual expenses, totaling US$4.2 billion, ...